Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
3
×
clinical trials
life sciences
national blog main
national top stories
new york blog main
3
×
biotech
boston blog main
boston top stories
eli lilly
merck
migraine
national
new york top stories
acorda therapeutics
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
allergan
alzheimer's disease
amgen
ampyra
antibiotics
apokyn
apomorphine
axial spondyloarthritis
bausch health
biogen
biohaven
boston university
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cancer immunotherapy
car-t immunotherapy
cell therapy
cgpr
What
new
3
×
approved
drug
fda
nod
treatment
acorda
adults
allergan
approval
bio
biogen’s
biopharmaceutical
class
companies
convo
cope
disease
earlier
episodes
failures
friday
gets
help
late
littered
looms
meant
medications
medicines
migraine
monday
nash
news
parkinson’s
patients
pill
price
remains
rival
Language
unset
Current search:
abbvie
×
new
×
" new york blog main "
×
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms